Publications by authors named "M J Ijsseldijk"
Objectives: Optimal treatment of stage IIIA (N2) non-small-cell lung cancer (NSCLC) is controversial. Guidelines advise induction therapy before surgical resection. A proportion of patients with cN0 NSCLC are postoperatively upstaged due to unsuspected N2 disease.
View Article and Find Full Text PDFBackground: The optimal treatment of stage I non-small-cell lung carcinoma is subject to debate. The aim of this study was to compare overall survival and oncologic outcomes of lobar resection (LR), sublobar resection (SR), and stereotactic body radiotherapy (SBRT).
Methods: A systematic review and meta-analysis of oncologic outcomes of propensity matched comparative and noncomparative cohort studies was performed.
A validation study for a clinical decision rule for acute wrist injury.
Eur J Trauma Emerg Surg
December 2022
Purpose: Acute wrist injury is a common reason for visiting the emergency department. To date, there are no implemented clinical decision rules to predict a fracture in this group of patients. We previously identified six clinical predictors in adult patients with acute wrist trauma.
View Article and Find Full Text PDFArticle Synopsis
- Early-stage non-small-cell lung cancer (NSCLC) treatment is debated; lobar resection is standard, but sublobar resections, which preserve lung tissue, show promising results.
- A systematic review and meta-analysis compared outcomes between lobar resections and parenchymal-sparing techniques for T1a NSCLC, analyzing data from 28 studies.
- Findings indicate no significant difference in 5-year overall survival rates between the two surgical approaches, although parenchymal-sparing surgery may present risks related to nodal upstaging in patients who could tolerate lobectomy.
Article Synopsis
- SBRT is a potentially curative treatment for early-stage NSCLC, but its survival outcomes might vary based on whether the diagnosis is clinically or biopsy-proven.
- The systematic review analyzed 43 studies, revealing that patients with biopsy-proven disease had lower 3-year overall survival and cancer-specific survival rates compared to those diagnosed clinically, although 5-year overall survival rates were similar for both groups.
- The findings underline the significance of obtaining pathological confirmation of malignancy before treating with SBRT, as this could impact patient outcomes.